STE · 10-Q · 2026Q3 · Full report

Operating Expense Trends

STERIS plc · 2026-11-05 · Importance 29 · Surprise 22

For the six months ended September 30, 2026, SG&A increased 4.6% to $735.7 million, primarily from compensation and benefit costs, professional fees, and dealer commissions, partly offset by favorable foreign currency movements and lower depreciation and amortization. Research and development expense increased 10.2% to $60.2 million for the six-month period and 11.7% to $31.5 million in the quarter. Fiscal 2027 R&D investment focused on sterile processing technologies, procedural products and accessories, and gastrointestinal endoscopy devices and support accessories.

Key facts

• STERIS research and development expenses increased 11.7% in the three months and 10.2% in the six months ended September 30, 2026. source
• STERIS acquisition and integration expenses were $4.0 million and $5.5 million for the three and six months ended September 30, 2026, respectively, compared with $1.3 million and $1.8 million for the corresponding 2025 periods. source
• STERIS SG&A increased 4.6% in both the three and six months ended September 30, 2026; quarterly growth reflected higher professional fees and dealer commissions, partly offset by lower compensation and depreciation and amortization. source
• STERIS identifies strikes, unsuccessful union negotiations, workforce disruptions, and inability to recruit or retain personnel as operational risks. source